Lapatinib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lapatinib" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

10doi.org

2^nd place

5web.archive.org

1^st place

3semanticscholar.org

11^th place

8^th place

1fda.gov

447^th place

338^th place

1europa.eu

68^th place

117^th place

1gsk.com

low place

1medicalnewstoday.com

3,011^th place

2,709^th place

1reuters.com

49^th place

47^th place

1ecco-org.eu

low place

1cancer.gov

1,684^th place

1,350^th place

1bioportfolio.com

low place

bioportfolio.com

"Tykerb/Tyverb Phase III gastric cancer study fails to meet primary endpoint". Archived from the original on 10 January 2015.

cancer.gov

"FDA Approval for Lapatinib Ditosylate (Tykerb®)". NCI Cancer Drug Information. Archived from the original on 6 April 2015.

doi.org

Burris HA (2004). "Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib". The Oncologist. 9 (Suppl 3): 10–15. doi:10.1634/theoncologist.9-suppl_3-10. PMID 15163842. S2CID 38907784.
Higa GM, Abraham J (September 2007). "Lapatinib in the treatment of breast cancer". Expert Review of Anticancer Therapy. 7 (9): 1183–1192. doi:10.1586/14737140.7.9.1183. PMID 17892419. S2CID 36837880.
"Breast cancer drug approved for new indication". Women's Health. 6 (2). Cancer.gov: 173. March 2010. doi:10.2217/whe.10.11. PMID 20187722.
Cragg GM, Grothaus PG, Newman DJ (July 2009). "Impact of natural products on developing new anti-cancer agents". Chemical Reviews. 109 (7): 3012–43. doi:10.1021/cr900019j. PMID 19422222.
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. (September 2004). "A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells". Cancer Research. 64 (18): 6652–6659. doi:10.1158/0008-5472.CAN-04-1168. PMID 15374980.{{cite journal}}: CS1 maint: overridden setting (link)
Nelson MH, Dolder CR (February 2006). "Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors". The Annals of Pharmacotherapy. 40 (2): 261–269. doi:10.1345/aph.1G387. PMID 16418322. S2CID 21622641.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. (December 2006). "Lapatinib plus capecitabine for HER2-positive advanced breast cancer". The New England Journal of Medicine. 355 (26): 2733–2743. doi:10.1056/NEJMoa064320. PMID 17192538.{{cite journal}}: CS1 maint: overridden setting (link)
Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, et al. (May 2014). "Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer". Journal of Clinical Oncology. 32 (14): 1472–1479. doi:10.1200/JCO.2013.52.1161. PMC 4017711. PMID 24711549.{{cite journal}}: CS1 maint: overridden setting (link)
Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. (August 2005). "Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas". Journal of Clinical Oncology. 23 (23): 5305–5313. doi:10.1200/JCO.2005.16.584. PMID 15955900.{{cite journal}}: CS1 maint: overridden setting (link)
Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, et al. (August 2016). "Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial". Journal of the National Cancer Institute. 108 (8): djw037. doi:10.1093/jnci/djw037. PMC 5017935. PMID 27098150.{{cite journal}}: CS1 maint: overridden setting (link)

ecco-org.eu

Rodriguez A (April 2008). New type of drug shrinks primary breast cancer tumors significantly in just six weeks; research provides leads to a new target in cancer treatment – the cancer stem cell. Archived from the original on 26 November 2008.

europa.eu

ema.europa.eu

"Tyverb EPAR". European Medicines Agency (EMA). 10 June 2008. Retrieved 12 October 2024.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

gsk.com

"GlaxoSmithKline receives marketing authorisation in the EU for Tyverb (lapatinib), the first oral targeted therapy for ErbB2-positive breast cancer" (Press release). GlaxoSmithKline. 12 June 2008. Archived from the original on 15 June 2008. Retrieved 21 June 2008.

medicalnewstoday.com

"GlaxoSmithKline Reports Positive New Data On Tykerb (lapatinib) At The 2007 American Society Of Clinical Oncology (ASCO) Annual Meeting" (Press release). Medical News Today. 4 June 2007. Archived from the original on 13 April 2010. Retrieved 2 December 2008. Retrieved December 2, 2008.

nih.gov

pubmed.ncbi.nlm.nih.gov

Burris HA (2004). "Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib". The Oncologist. 9 (Suppl 3): 10–15. doi:10.1634/theoncologist.9-suppl_3-10. PMID 15163842. S2CID 38907784.
Higa GM, Abraham J (September 2007). "Lapatinib in the treatment of breast cancer". Expert Review of Anticancer Therapy. 7 (9): 1183–1192. doi:10.1586/14737140.7.9.1183. PMID 17892419. S2CID 36837880.
"Breast cancer drug approved for new indication". Women's Health. 6 (2). Cancer.gov: 173. March 2010. doi:10.2217/whe.10.11. PMID 20187722.
Cragg GM, Grothaus PG, Newman DJ (July 2009). "Impact of natural products on developing new anti-cancer agents". Chemical Reviews. 109 (7): 3012–43. doi:10.1021/cr900019j. PMID 19422222.
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. (September 2004). "A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells". Cancer Research. 64 (18): 6652–6659. doi:10.1158/0008-5472.CAN-04-1168. PMID 15374980.{{cite journal}}: CS1 maint: overridden setting (link)
Nelson MH, Dolder CR (February 2006). "Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors". The Annals of Pharmacotherapy. 40 (2): 261–269. doi:10.1345/aph.1G387. PMID 16418322. S2CID 21622641.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. (December 2006). "Lapatinib plus capecitabine for HER2-positive advanced breast cancer". The New England Journal of Medicine. 355 (26): 2733–2743. doi:10.1056/NEJMoa064320. PMID 17192538.{{cite journal}}: CS1 maint: overridden setting (link)
Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, et al. (May 2014). "Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer". Journal of Clinical Oncology. 32 (14): 1472–1479. doi:10.1200/JCO.2013.52.1161. PMC 4017711. PMID 24711549.{{cite journal}}: CS1 maint: overridden setting (link)
Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. (August 2005). "Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas". Journal of Clinical Oncology. 23 (23): 5305–5313. doi:10.1200/JCO.2005.16.584. PMID 15955900.{{cite journal}}: CS1 maint: overridden setting (link)
Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, et al. (August 2016). "Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial". Journal of the National Cancer Institute. 108 (8): djw037. doi:10.1093/jnci/djw037. PMC 5017935. PMID 27098150.{{cite journal}}: CS1 maint: overridden setting (link)

ncbi.nlm.nih.gov

Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, et al. (May 2014). "Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer". Journal of Clinical Oncology. 32 (14): 1472–1479. doi:10.1200/JCO.2013.52.1161. PMC 4017711. PMID 24711549.{{cite journal}}: CS1 maint: overridden setting (link)
Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, et al. (August 2016). "Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial". Journal of the National Cancer Institute. 108 (8): djw037. doi:10.1093/jnci/djw037. PMC 5017935. PMID 27098150.{{cite journal}}: CS1 maint: overridden setting (link)

reuters.com

Kulkarni K (2 August 2013). "India revokes GSK cancer drug patent in latest Big Pharma blow". Reuters. Mumbai, India. Retrieved 2 August 2013.

semanticscholar.org

api.semanticscholar.org

Burris HA (2004). "Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib". The Oncologist. 9 (Suppl 3): 10–15. doi:10.1634/theoncologist.9-suppl_3-10. PMID 15163842. S2CID 38907784.
Higa GM, Abraham J (September 2007). "Lapatinib in the treatment of breast cancer". Expert Review of Anticancer Therapy. 7 (9): 1183–1192. doi:10.1586/14737140.7.9.1183. PMID 17892419. S2CID 36837880.
Nelson MH, Dolder CR (February 2006). "Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors". The Annals of Pharmacotherapy. 40 (2): 261–269. doi:10.1345/aph.1G387. PMID 16418322. S2CID 21622641.

web.archive.org

"GlaxoSmithKline receives marketing authorisation in the EU for Tyverb (lapatinib), the first oral targeted therapy for ErbB2-positive breast cancer" (Press release). GlaxoSmithKline. 12 June 2008. Archived from the original on 15 June 2008. Retrieved 21 June 2008.
"GlaxoSmithKline Reports Positive New Data On Tykerb (lapatinib) At The 2007 American Society Of Clinical Oncology (ASCO) Annual Meeting" (Press release). Medical News Today. 4 June 2007. Archived from the original on 13 April 2010. Retrieved 2 December 2008. Retrieved December 2, 2008.
Rodriguez A (April 2008). New type of drug shrinks primary breast cancer tumors significantly in just six weeks; research provides leads to a new target in cancer treatment – the cancer stem cell. Archived from the original on 26 November 2008.
"FDA Approval for Lapatinib Ditosylate (Tykerb®)". NCI Cancer Drug Information. Archived from the original on 6 April 2015.
"Tykerb/Tyverb Phase III gastric cancer study fails to meet primary endpoint". Archived from the original on 10 January 2015.